Amoy Diagnostics (300685.SZ): AmoyDx PIK3CA gene mutation test kit approved in Japan.
Adlai Biological (300685.SZ) announced that its self-developed product, the AmoyDx PIK3CA gene mutation detection kit, has recently been approved for marketing by the Japanese Ministry of Health, Labor and Welfare.
Amoy Diagnostics (300685.SZ) announced that its self-developed product, the AmoyDx PIK3CA gene mutation test kit, has recently been approved for market listing by the Ministry of Health, Labour and Welfare of Japan.
This product provides accurate test results, high success rate, stable performance, requires a small sample size, and has a fast reporting speed. It is a companion diagnostic reagent for the novel PI3K selective inhibitor sulfosuccinimidyl-Fabsotsulap (Riesolisilap Fabsot) for the treatment of cancer. This approval further enriches the company's tumor companion diagnostic product line, enhances the company's competitiveness in overseas markets, improves the company's market expansion capabilities, and will have a positive impact on the company's future development.
Related Articles
JXR (01951) Southern Headquarters set up a "one yard, two centers" to serve the Greater Bay Area and radiate Southeast Asia from Shenzhen.
Revenue of 66.666 billion, net profit of 8.3 billion, deep digging into the investment certainty behind HENLIUS (02696) 2025 annual report
Shareholders' net profit increased by 1.5 times, is the gold bull stock ZHAOJIN MINING (01818) expected to have potential in 2025?
JXR (01951) Southern Headquarters set up a "one yard, two centers" to serve the Greater Bay Area and radiate Southeast Asia from Shenzhen.
Revenue of 66.666 billion, net profit of 8.3 billion, deep digging into the investment certainty behind HENLIUS (02696) 2025 annual report
Shareholders' net profit increased by 1.5 times, is the gold bull stock ZHAOJIN MINING (01818) expected to have potential in 2025?
